T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.15B |
| 2 |
Amphenol
APH
|
+$757M |
| 3 |
Advanced Micro Devices
AMD
|
+$658M |
| 4 |
PTC
PTC
|
+$524M |
| 5 |
Zscaler
ZS
|
+$519M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$976M |
| 2 |
Mastercard
MA
|
+$804M |
| 3 |
Fortinet
FTNT
|
+$638M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$618M |
| 5 |
Visa
V
|
+$600M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.65% |
| 2 | Healthcare | 20.51% |
| 3 | Consumer Discretionary | 12.57% |
| 4 | Industrials | 11.2% |
| 5 | Financials | 10.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
LCI Industries
LCII
$2.62B
| $7.26M | ﹤0.01% |
83,050
-225,805
| -73% | -$22.7M |
|
577
Walt Disney
DIS
$179B
| $7.01M | ﹤0.01% |
71,025
+18,525
| +35% | +$1.99M |
|
578
CAVA Group
CAVA
$8.27B
| $6.46M | ﹤0.01% |
74,784
-10,708
| -13% | -$1.16M |
|
579
Iovance Biotherapeutics
IOVA
$2.95B
| $6.43M | ﹤0.01% |
1,930,020
-3,904,436
| -67% | -$20.1M |
|
580
Applied Materials
AMAT
$443B
| $6.26M | ﹤0.01% |
43,115
+40,453
| +1,520% | +$6.8M |
|
581
Commercial Metals
CMC
$7.95B
| $6.25M | ﹤0.01% |
+135,896
| New | +$6.61M |
|
582
Patrick Industries
PATK
$2.81B
| $6.08M | ﹤0.01% |
+71,837
| New | +$6.46M |
|
583
Pacific Biosciences
PACB
$357M
| $5.77M | ﹤0.01% |
4,888,612
-8,232
| -0.2% | -$12.6K |
|
584
Ametek
AME
$58.7B
| $5.7M | ﹤0.01% |
33,126
-30,531
| -48% | -$5.55M |
|
585
Cabaletta Bio
CABA
$445M
| $5.5M | ﹤0.01% |
3,970,026
-103,980
| -3% | -$222K |
|
586
Flywire
FLYW
$2.14B
| $5.18M | ﹤0.01% |
545,601
-348,353
| -39% | -$5.48M |
|
|
APLT
587
DELISTED
Applied Therapeutics
APLT
| $5.08M | ﹤0.01% |
10,380,590
+4,959,670
| +91% | +$2.92M |
|
588
Privia Health
PRVA
$2.79B
| $4.92M | ﹤0.01% |
219,058
-3,555,698
| -94% | -$82.6M |
|
589
Tango Therapeutics
TNGX
$4.32B
| $4.54M | ﹤0.01% |
3,312,449
-33,102
| -1% | -$81.3K |
|
|
BBOT
590
BridgeBio Oncology
BBOT
$755M
| $4.5M | ﹤0.01% |
397,962
-2,285
| -0.6% | -$24.6K |
|
591
Orion
OEC
$363M
| $4.12M | ﹤0.01% |
318,376
-944,232
| -75% | -$13.4M |
|
592
Lam Research
LRCX
$425B
| $4.1M | ﹤0.01% |
56,397
-90,883
| -62% | -$7.16M |
|
|
SEZL
593
Sezzle
SEZL
$4.39B
| $4.01M | ﹤0.01% |
+114,960
| New | +$4.87M |
|
594
Arvinas
ARVN
$584M
| $3.85M | ﹤0.01% |
548,104
-1,660,130
| -75% | -$26M |
|
595
Tetra Tech
TTEK
$9.02B
| $3.5M | ﹤0.01% |
119,505
-1,317,099
| -92% | -$44.2M |
|
596
Eagle Materials
EXP
$6.46B
| $3.29M | ﹤0.01% |
14,815
-20,331
| -58% | -$4.82M |
|
597
Jasper Therapeutics
JSPR
$28.6M
| $3.02M | ﹤0.01% |
702,757
+620,592
| +755% | +$4.13M |
|
598
Grid Dynamics Holdings
GDYN
$630M
| $2.97M | ﹤0.01% |
189,962
-508,848
| -73% | -$10.2M |
|
599
Toro Company
TTC
$9.24B
| $2.36M | ﹤0.01% |
32,442
-1,253
| -4% | -$99K |
|
|
TLN
600
Talen Energy Corp
TLN
$17.2B
| $2.35M | ﹤0.01% |
11,751
-13,087
| -53% | -$2.84M |
|
Similar funds
T. Rowe Price Investment Management's Q1 2025 Portfolio in Review
As of Q1 2025, T. Rowe Price Investment Management held 707 positions worth $151B, down 6.7% from $162B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
T. Rowe Price Investment Management's Q1 2025 filing shows 74 new, 322 increased, 258 reduced and 50 closed positions. Its largest new stake was Zscaler: 2,603,675 shares worth $517M. The largest sale was UnitedHealth, an estimated $976M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Investment Management's largest Q1 2025 buy was Zscaler: 2,603,675 shares worth $517M.
- T. Rowe Price Investment Management added most to Microsoft in Q1 2025, an estimated $1.15B increase.
- T. Rowe Price Investment Management's biggest Q1 2025 reduction was UnitedHealth, cutting an estimated $976M.
- T. Rowe Price Investment Management fully exited Five Below in Q1 2025, selling an estimated $378M.
- T. Rowe Price Investment Management's ten largest holdings make up 19% of its $151B portfolio in Q1 2025.
- T. Rowe Price Investment Management opened 74 new positions and closed 50 in Q1 2025.
- T. Rowe Price Investment Management's portfolio value fell 6.7% quarter-over-quarter to $151B.
Based on T. Rowe Price Investment Management's 13F filing for Q1 2025, filed 14 May 2025.